NIT
CLDX icon

NumerixS Investment Technologies’s Celldex Therapeutics CLDX Stock Holding History

NumerixS Investment Technologies’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,036
Closed -$150K – 1176
2017
Q2 		$150K Buy
+4,036
New +$179K 0.02% 733
2017
Q1 		– Sell
-2,753
Closed -$146K – 1179
2016
Q4 		$146K Buy
+2,753
New +$157K 0.02% 769

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

NumerixS Investment Technologies's CLDX Position: Q3 2017 in Review

NumerixS Investment Technologies sold out of Celldex Therapeutics (CLDX) in Q3 2017, closing a stake of 4,036 shares — an estimated $150K sold.

NumerixS Investment Technologies first reported a position in CLDX in Q4 2016 and held it in 2 quarters. The position peaked at $150K in Q2 2017. 129 funds tracked by Wall St. Rank hold CLDX as of Q3 2017.

  • NumerixS Investment Technologies reported no remaining Celldex Therapeutics position as of Q3 2017 after selling out during the quarter.
  • NumerixS Investment Technologies sold 4,036 Celldex Therapeutics shares in Q3 2017, an estimated $150K.
  • NumerixS Investment Technologies first reported a position in Celldex Therapeutics in Q4 2016 and held it in 2 quarters.
  • NumerixS Investment Technologies's Celldex Therapeutics position peaked at $150K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2017.

Based on NumerixS Investment Technologies's 13F filing for Q3 2017, filed 13 Nov 2017.